Collaborative, Licensing and Other Arrangements - Pfizer - Additional Information (Details) - Collaborative Arrangement [Member] - Pfizer Inc. [Member] - USD ($) |
12 Months Ended | 60 Months Ended | ||
|---|---|---|---|---|
Dec. 03, 2015 |
Dec. 31, 2017 |
Dec. 31, 2016 |
Dec. 31, 2015 |
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
| Milestone received under the collaboration agreement | $ 4,200,000 | |||
| Amount received from settlement of the Pfizer agreement | $ 3,800,000 | |||
| Royalties earned from sale | $ 0 | $ 400,000 | ||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Cash received for royalties during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount received from settlement of agreement. No definition available.
|
| X | ||||||||||
- Definition Refers to the payment percentage of milestone received under the collaboration agreement. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|